Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Outperform at Leerink Partners

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Wednesday, MarketBeat.com reports. The firm currently has $834.00 price target on the biopharmaceutical company's stock, up from their prior price target of $762.00.

REGN has been the topic of several other reports. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research note on Tuesday. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Up 0.4 %

NASDAQ REGN traded up $2.67 during mid-day trading on Wednesday, reaching $719.39. 619,516 shares of the stock were exchanged, compared to its average volume of 935,037. The stock has a market capitalization of $79.05 billion, a PE ratio of 17.83, a PEG ratio of 1.60 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals has a 1-year low of $642.00 and a 1-year high of $1,211.20. The business's fifty day simple moving average is $717.27 and its 200 day simple moving average is $914.93.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The business's revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $11.86 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.49%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Oak Grove Capital LLC increased its stake in Regeneron Pharmaceuticals by 48.0% during the fourth quarter. Oak Grove Capital LLC now owns 2,930 shares of the biopharmaceutical company's stock valued at $2,087,000 after purchasing an additional 950 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 44.8% during the 4th quarter. Victory Capital Management Inc. now owns 139,891 shares of the biopharmaceutical company's stock valued at $99,649,000 after buying an additional 43,282 shares during the last quarter. Keybank National Association OH grew its position in shares of Regeneron Pharmaceuticals by 6.5% during the 4th quarter. Keybank National Association OH now owns 1,239 shares of the biopharmaceutical company's stock valued at $883,000 after buying an additional 76 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its stake in Regeneron Pharmaceuticals by 49.5% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 601 shares of the biopharmaceutical company's stock worth $423,000 after acquiring an additional 199 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock worth $495,639,000 after acquiring an additional 22,538 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.